Literature DB >> 517183

Optimal therapy in medulloblastoma.

E B Bongartz, M Bamberg, H E Nau, G Schmitt, C Bayindir.   

Abstract

Twenty-eight children with medulloblastoma (19 boys and 9 girls) were treated at the Departments of Neurosurgery and Radiotherapy in Essen between 1969 and 1977, and were followed prospectively after surgical treatment and postoperative irradiation. Because different radiation techniques had been used, these patients were divided into two groups, one given a limited irradiation volume and the other irradiation of the entire central nervous system. The results obtained in the former group were inferior to those in the latter. All living patients in the seond group are in good condition. Special attention is paid to the technique of irradiation and the factors which may influence prognosis. Even after the relatively short follow up period of one to five years, it may be concluded that high-dose irradiation of the entire central nervous system considerably improved the prognosis of medulloblastoma.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 517183     DOI: 10.1007/bf01813556

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  11 in total

1.  Improved survival of patients with intracranial ependymomas by irradiation: doseselection and field extension.

Authors:  O M Salazar; P Rubin; D Bassano; V A Marcial
Journal:  Cancer       Date:  1975-06       Impact factor: 6.860

2.  Medulloblastoma. A review of the LDS hospital experience.

Authors:  R C Brown; L Gunderson; H P Plenk
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

3.  Growth retardation in children after megavoltage irradiation of the spine.

Authors:  J C Probert; B R Parker; H S Kaplan
Journal:  Cancer       Date:  1973-09       Impact factor: 6.860

4.  Medulloblastoma: an analysis of time-dose relationships and recurrence patterns.

Authors:  C E Smith; D M Long; T K Jones; S H Levitt
Journal:  Cancer       Date:  1973-09       Impact factor: 6.860

5.  The treatment and prognosis of medulloblastoma in children. A study of 82 verified cases.

Authors:  H J Bloom; E N Wallace; J M Henk
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1969-01

6.  An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas.

Authors:  C H Chang; E M Housepian; C Herbert
Journal:  Radiology       Date:  1969-12       Impact factor: 11.105

7.  Medulloblastoma: prognosis and prospects.

Authors:  H J Bloom
Journal:  Int J Radiat Oncol Biol Phys       Date:  1977 Sep-Oct       Impact factor: 7.038

8.  Medulloblastoma in children: a correlation between staging and results of treatment.

Authors:  L Harisiadis; C H Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  1977 Sep-Oct       Impact factor: 7.038

9.  Medulloblastoma: treatment technique and radiation dosimetry.

Authors:  J Van Dyk; R D Jenkin; P M Leung; J R Cunningham
Journal:  Int J Radiat Oncol Biol Phys       Date:  1977 Sep-Oct       Impact factor: 7.038

10.  Period of risk for recurrence in medulloblastoma.

Authors:  D O Quest; R Brisman; J L Antunes; E M Housepian
Journal:  J Neurosurg       Date:  1978-02       Impact factor: 5.115

View more
  4 in total

Review 1.  Medulloblastomas: a review of 11 cases.

Authors:  J Gómez Perún; L Carcavilla; J Eiras; J Alberdi; J Pisón; T Arana
Journal:  Childs Nerv Syst       Date:  1987       Impact factor: 1.475

2.  Early response and long-term results in the radiotherapy of childhood medulloblastoma.

Authors:  H W Chin; Y Maruyama
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

3.  Management of medulloblastoma in children, a multidisciplinary problem.

Authors:  G Broere
Journal:  Neurosurg Rev       Date:  1986       Impact factor: 3.042

4.  Treatment of medulloblastoma in children: long-term results following surgery, radiotherapy and chemotherapy.

Authors:  C Mazza; A Pasqualin; R Da Pian; E Donati
Journal:  Acta Neurochir (Wien)       Date:  1981       Impact factor: 2.216

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.